Although concurrent depletion of EGR4 and ZNF205‐AS1 for clinical application is difficult until now, but the combination of EGR4 inhibitor and ZNF205‐AS1 siRNA therapeutics in the future may be promising therapeutic strategy for NSCLC. This evidence concerns the gene EGR4 and non-small cell lung carcinoma.